Search research articles
Contact Us
Filters
Showing results (281-290 of 362) with videos related to
Page
of 37
Sort By:
Inflammatory Bowel Diseases
|
September 23, 2020
Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease
Mark T Osterman, Kelli L VanDussen, Ilyssa O Gordon, et al.
Journal of the American College of Cardiology
|
March 5, 2021
Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function
Iris E Beldhuis, Peder L Myhre, Michael Bristow, et al.
JACC. Heart Failure
|
October 31, 2025
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure
James E Udelson, Jan Bělohlávek, Andrej Dukát, et al.
JACC. Heart Failure
|
November 21, 2024
Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF Trial
Finnian R Mc Causland, Muthiah Vaduganathan, Brian Claggett, et al.
European Journal of Heart Failure
|
May 29, 2021
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
Scott D Solomon, Rudolf A de Boer, David DeMets, et al.
Circulation. Heart Failure
|
October 22, 2021
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction
Masatoshi Minamisawa, Brian Claggett, Kota Suzuki, et al.
European Journal of Heart Failure
|
January 6, 2022
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure
Finnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
European Journal of Heart Failure
|
September 2, 2022
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial
Otavio Berwanger, Marc Pfeffer, Brian Claggett, et al.
Circulation
|
August 27, 2020
Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction
Finnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
The New England Journal of Medicine
|
December 3, 2015
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A Pfeffer, Brian Claggett, Rafael Diaz, et al.
Page
of 37
Search research articles
Search
Showing results (281-290 of 362) with videos related to
Sort By:
Page
of 37
Inflammatory Bowel Diseases
|
September 23, 2020
Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease
Mark T Osterman, Kelli L VanDussen, Ilyssa O Gordon, et al.
Journal of the American College of Cardiology
|
March 5, 2021
Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function
Iris E Beldhuis, Peder L Myhre, Michael Bristow, et al.
JACC. Heart Failure
|
October 31, 2025
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure
James E Udelson, Jan Bělohlávek, Andrej Dukát, et al.
JACC. Heart Failure
|
November 21, 2024
Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF Trial
Finnian R Mc Causland, Muthiah Vaduganathan, Brian Claggett, et al.
European Journal of Heart Failure
|
May 29, 2021
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
Scott D Solomon, Rudolf A de Boer, David DeMets, et al.
Circulation. Heart Failure
|
October 22, 2021
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction
Masatoshi Minamisawa, Brian Claggett, Kota Suzuki, et al.
European Journal of Heart Failure
|
January 6, 2022
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure
Finnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
European Journal of Heart Failure
|
September 2, 2022
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial
Otavio Berwanger, Marc Pfeffer, Brian Claggett, et al.
Circulation
|
August 27, 2020
Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction
Finnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
The New England Journal of Medicine
|
December 3, 2015
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A Pfeffer, Brian Claggett, Rafael Diaz, et al.
Page
of 37